Correlation Between Protalix Biotherapeutics and Fulcrum Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Protalix Biotherapeutics and Fulcrum Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Protalix Biotherapeutics and Fulcrum Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Protalix Biotherapeutics and Fulcrum Therapeutics, you can compare the effects of market volatilities on Protalix Biotherapeutics and Fulcrum Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Protalix Biotherapeutics with a short position of Fulcrum Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Protalix Biotherapeutics and Fulcrum Therapeutics.

Diversification Opportunities for Protalix Biotherapeutics and Fulcrum Therapeutics

-0.15
  Correlation Coefficient

Good diversification

The 3 months correlation between Protalix and Fulcrum is -0.15. Overlapping area represents the amount of risk that can be diversified away by holding Protalix Biotherapeutics and Fulcrum Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Fulcrum Therapeutics and Protalix Biotherapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Protalix Biotherapeutics are associated (or correlated) with Fulcrum Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Fulcrum Therapeutics has no effect on the direction of Protalix Biotherapeutics i.e., Protalix Biotherapeutics and Fulcrum Therapeutics go up and down completely randomly.

Pair Corralation between Protalix Biotherapeutics and Fulcrum Therapeutics

Considering the 90-day investment horizon Protalix Biotherapeutics is expected to generate 1.08 times more return on investment than Fulcrum Therapeutics. However, Protalix Biotherapeutics is 1.08 times more volatile than Fulcrum Therapeutics. It trades about 0.35 of its potential returns per unit of risk. Fulcrum Therapeutics is currently generating about 0.16 per unit of risk. If you would invest  120.00  in Protalix Biotherapeutics on September 12, 2024 and sell it today you would earn a total of  60.00  from holding Protalix Biotherapeutics or generate 50.0% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Protalix Biotherapeutics  vs.  Fulcrum Therapeutics

 Performance 
       Timeline  
Protalix Biotherapeutics 

Risk-Adjusted Performance

16 of 100

 
Weak
 
Strong
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Protalix Biotherapeutics are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain essential indicators, Protalix Biotherapeutics showed solid returns over the last few months and may actually be approaching a breakup point.
Fulcrum Therapeutics 

Risk-Adjusted Performance

7 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Fulcrum Therapeutics are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain essential indicators, Fulcrum Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point.

Protalix Biotherapeutics and Fulcrum Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Protalix Biotherapeutics and Fulcrum Therapeutics

The main advantage of trading using opposite Protalix Biotherapeutics and Fulcrum Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Protalix Biotherapeutics position performs unexpectedly, Fulcrum Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Fulcrum Therapeutics will offset losses from the drop in Fulcrum Therapeutics' long position.
The idea behind Protalix Biotherapeutics and Fulcrum Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Other Complementary Tools

Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Equity Valuation
Check real value of public entities based on technical and fundamental data